Biotech

Chutes & Ladders—Viatris appoints Pfizer CFO Narula to C-suite

Chutes & Ladders—Viatris appoints Pfizer CFO Narula to...

Pfizer, Mylan vets move over to generics merger Viatris; Spark CMO Reape steps down;...

Biogen puts down massive $350M upfront for Sangamo preclinical assets

Biogen puts down massive $350M upfront for Sangamo preclinical...

A year ago, Sangamo’s shares sank after it posted lackluster data for its genome-editing...

Gilead hungry for 'don't eat me' cancer biotech: reports

Gilead hungry for 'don't eat me' cancer biotech: reports

A new decade, the same old game: It’s time to play, who will Gilead buy? Sources...

Boehringer taps Trutino to bag safer, more efficacious cytokines

Boehringer taps Trutino to bag safer, more efficacious...

Boehringer Ingelheim has struck a deal with Trutino Biosciences to develop three...

Trial sponsors set to report a decade of old data after judge finds FDA rule unlawful

Trial sponsors set to report a decade of old data after...

A federal judge has ruled that sponsors need to share results from a decade’s worth...

How muting an RNA molecule in immune cells could fight fatty liver disease in obesity

How muting an RNA molecule in immune cells could fight...

Researchers in Sweden found that in obesity, immune cells known as macrophages contribute...

Former Biogen CEO Scangos to be BIO'S COVID-19 czar: report

Former Biogen CEO Scangos to be BIO'S COVID-19 czar: report

The chief executive of infectious disease biotech Vir, George Scangos, has been...

Waksal's bid for Redx ends, forcing biotech to avert cash crunch

Waksal's bid for Redx ends, forcing biotech to avert cash...

Sam Waksal’s attempt to buy Redx Pharma has fallen apart. The failure of a company...

Gilead strikes $4.9B Forty Seven acquisition, paying a hefty premium for cancer drug

Gilead strikes $4.9B Forty Seven acquisition, paying a...

The takeover will give Gilead control of midphase anti-CD47 antibody magrolimab...

Autism discoveries point to potential protein-targeted treatments

Autism discoveries point to potential protein-targeted...

Scientists at the Gladstone Institutes discovered a link between the Alzheimer's-associated...

Immunocore raises $130M to fund pivotal cancer program

Immunocore raises $130M to fund pivotal cancer program

Immunocore has raised a $130 million (€117 million) series B round, ending its long...

CRO BioPharma Services hands over early-stage facility for COVID-19 research

CRO BioPharma Services hands over early-stage facility...

With the first deaths being registered in North America this week, contract research...

Unum dumps clinical work, slashes 60% of workforce as CSO walks

Unum dumps clinical work, slashes 60% of workforce as CSO...

After a tough few years that saw a bottom-of-the-range IPO and several clinical...

Altavant nabs Boehringer, Gilead alum as new CMO

Altavant nabs Boehringer, Gilead alum as new CMO

While no longer a member of Vivek Ramaswamy’s Roivant umbrella group, his former...

Biogen's early R&D chief Ghosh leaves to take Unity CEO post

Biogen's early R&D chief Ghosh leaves to take Unity CEO...

Biogen’s head of early R&D Anirvan Ghosh has left the company to take up the CEO...

BARDA rejects Pluristem's request for radiation study funding

BARDA rejects Pluristem's request for radiation study funding

The U.S. Biomedical Advanced Research and Development Authority has rejected Pluristem...

Senti hires Iglesias, of Abraxane fame, to lead push into clinic

Senti hires Iglesias, of Abraxane fame, to lead push into...

Senti Biosciences has named Jose Iglesias as its chief medical officer. Iglesias...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.